Ferrari R, Cargnoni A, Ceconi C, Curello S, Belloli S, Albertini A, Visioli O
Cattedra di Cardiologia e di Chimica, Universita' degli Studi di Brescia, Italia.
J Mol Cell Cardiol. 1988 Dec;20(12):1095-106. doi: 10.1016/0022-2828(88)90590-1.
To assess whether the administration of the stable prostacyclin-mimetic ZK 36374 (iloprost) protects the myocardium in a dose-dependent manner against ischaemia and reperfusion, isolated rabbit hearts were infused with three different concentrations of iloprost: 2.7, 27 and 270 nM. Diastolic and developed pressures were monitored; coronary effluent was collected and assayed for creatine phosphokinase (CPK) activity and for noradrenaline concentration; mitochondria were harvested and assayed for respiratory activity; ATP production and calcium content and tissue concentration of adenosine triphosphate (ATP) and creatine phosphate (CP) were determined. Treatment with iloprost altered neither developed pressure under normoxic conditions nor the rate and extent of depletion of ATP and CP during ischaemia. The ischaemic-induced deterioration of mitochondrial function, however, was attenuated. On reperfusion, hearts treated with iloprost recovered better than the untreated hearts with respect to left ventricular performance, replenishment of ATP and CP stores and mitochondrial function. The reperfusion-induced mitochondrial calcium overload and release of CPK and of noradrenaline were also significantly reduced. The effect of iloprost was dose-dependent. The lower concentration (2.7 nM) failed to modify ischaemic and reperfusion damage. The best protective effect was found at 27 nM. An increase of the dose to 270 nM did not result in further protection. It is concluded that iloprost infusion provides a dose-dependent protection of the heart against some of the deleterious effects of ischaemia and reperfusion and, in particular, prevents mitochondrial calcium overload and maintains mitochondrial function. Because this protection occurred in the absence of negative inotropic effect during normoxia or of a coronary dilatory effect during ischaemia, it cannot be attributed to an energy sparing effect or to improvement of oxygen delivery. Therefore, alternative mechanisms of action are to be considered.
为评估稳定的前列环素类似物ZK 36374(伊洛前列素)给药是否以剂量依赖方式保护心肌免受缺血和再灌注损伤,给离体兔心灌注三种不同浓度的伊洛前列素:2.7、27和270 nM。监测舒张期压力和收缩期压力;收集冠状动脉流出液并测定肌酸磷酸激酶(CPK)活性和去甲肾上腺素浓度;收获线粒体并测定呼吸活性;测定ATP生成、钙含量以及组织中三磷酸腺苷(ATP)和磷酸肌酸(CP)的浓度。伊洛前列素治疗既未改变常氧条件下的收缩期压力,也未改变缺血期间ATP和CP的消耗速率及程度。然而,缺血诱导的线粒体功能恶化有所减轻。再灌注时,伊洛前列素治疗的心脏在左心室功能、ATP和CP储备补充以及线粒体功能方面比未治疗的心脏恢复得更好。再灌注诱导的线粒体钙超载以及CPK和去甲肾上腺素的释放也显著减少。伊洛前列素的作用呈剂量依赖性。较低浓度(2.7 nM)未能改变缺血和再灌注损伤。在27 nM时发现最佳保护作用。将剂量增加到270 nM并未带来进一步保护。得出结论,灌注伊洛前列素可对心脏提供剂量依赖性保护,使其免受缺血和再灌注的一些有害影响,尤其是防止线粒体钙超载并维持线粒体功能。由于这种保护作用在常氧期间不存在负性肌力作用或缺血期间不存在冠状动脉扩张作用的情况下发生,因此不能将其归因于能量节省效应或氧输送改善。因此,应考虑其他作用机制。